Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Cabazitaxel in Unfit mCRPC
NCT01518283Phase 2Completed
- Sponsor
- SOGUG
- Start
- May 2012
- Primary completion
- Jun 2016
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel ginsenoside liposome injection in metastatic castration-resistant prostate cancer (mCRPC), sponsored by SOGUG. Started May 2012; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01518283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01518283.